Ge Qichao, Lin Yuan, Wang Mingwang, Zhu Jianwei, Zhang Qingqing, Wang Junjun, Yang Yufei, Zhangdi Hanjing, Guo Yuecheng, Wang Shanjuan, Lu Lungen
Department of Gastroenterology Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China.
Department of Gastroenterology Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Science Shanghai China.
Food Sci Nutr. 2025 Jul 16;13(7):e70627. doi: 10.1002/fsn3.70627. eCollection 2025 Jul.
The burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing, yet there is little understanding in the Western Pacific Region (WPR). This study aims to report the latest MASLD burden in the WPR from 1990 to 2021. This study obtained nonmalignant and total MASLD incidence, prevalence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years of healthy life lost due to disability (YLDs) from the Global Burden of Disease (GBD) database, and calculated age-standardized ratios (ASRs) for each indicator. Estimated annual percentage changes (EAPCs) were calculated using a log-transformed linear regression model. The age-period-cohort (APC) model was used to analyze regional MASLD-related deaths; the Bayesian age-period-cohort (BAPC) model was used to estimate future trends from 2022 to 2050. The incidence, prevalence, deaths, and DALYs of nonmalignant MASLD in the WPR in 2021 are 12 million, 359.2 million, 10,195 cases, and 0.24 million years, respectively. The WPR has a high incidence of MASLD in younger age groups, especially in males, with the 15-19-year-old male group being 1215.82 per 100,000. Mongolia has the highest relative risk of deaths and DALYs, while Japan, Singapore, and China are comparatively low. The proportion of deaths and DALYs due to nonmalignant MASLD is increasing. Nonmalignant MASLD is projected to be the dominant component of resulting deaths and DALYs by 2050 in some countries. The WPR burden of MASLD is increasing, with a high prevalence in younger individuals, indicating the need for early initiation of targeted and effective MASLD prevention.
代谢功能障碍相关脂肪性肝病（MASLD）的负担正在增加，但西太平洋地区（WPR）对此了解甚少。本研究旨在报告1990年至2021年WPR地区最新的MASLD负担情况。本研究从全球疾病负担（GBD）数据库中获取了非恶性和总的MASLD发病率、患病率、死亡率、伤残调整生命年（DALYs）、寿命损失年数（YLLs）以及因残疾导致的健康生命损失年数（YLDs），并计算了每个指标的年龄标准化率（ASRs）。使用对数变换线性回归模型计算估计年百分比变化（EAPCs）。采用年龄-时期-队列（APC）模型分析地区性MASLD相关死亡情况；使用贝叶斯年龄-时期-队列（BAPC）模型估计2022年至2050年的未来趋势。2021年WPR地区非恶性MASLD的发病率、患病率、死亡数和DALYs分别为1200万、3.592亿、10195例和24万年。WPR地区年轻年龄组中MASLD发病率较高，尤其是男性，15至19岁男性组每10万人中有1215.82例。蒙古的死亡和DALYs相对风险最高，而日本、新加坡和中国相对较低。非恶性MASLD导致的死亡和DALYs比例正在增加。预计到2050年，在一些国家非恶性MASLD将成为导致死亡和DALYs的主要因素。WPR地区的MASLD负担正在增加，年轻个体患病率较高，这表明需要尽早开展有针对性的有效MASLD预防工作。
